Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's ...

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Quest Diagnostics will offer the Roche pTau217 blood test, now cleared by the FDA, to assess Alzheimer's disease pathology, enabling less invasive diagnosis options.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 6 sources have reported it between 24 Aug 2026 and 26 Aug 2026.

◆ ◆ The Wire takeaway

You have a new FDA-cleared diagnostic tool to adopt that expands early Alzheimer’s detection via blood tests. This opens faster clinical access and new clinical pathways if you operate in neurodegenerative diagnostics.

◆ Coverage

6 sources · first reported 24 Aug 2026 · latest 26 Aug 2026

◆ Related on Wire

◆ Topics

DiagnosticsalzheimersdiagnosticsFDA-clearedblood-testhealthtech